Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

NCT03694236 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Potentially Resectable Stage II/IIIa NSCLC

Interventions

DRUG: durvalumab

Sponsor

Yonsei University